Structure via PubChem · Public domain (PubChem)
entrectinib
Sign in to saveAlso known as NMS-E628, RXDX-101
Entrectinib, sold under the brand name Rozlytrek, is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (TRK) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK).
In the Vinony graph
Vinony's link graph records 500 inbound references to entrectinib, and connects out to Colorectal cancer, orphan drug and salivary gland neoplasm.
It is catalogued under topics including 4-Methylpiperazin-1-yl compounds, Benzamides and Drugs developed by Genentech.
Vinony links it to 5 Wikipedia language editions.
Chemical data
- Formula
- C31H34F2N6O2
- Molecular weight
- 560.6 g/mol
- IUPAC name
- N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide
- SMILES
- CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6
- InChIKey
- HAYYBYPASCDWEQ-UHFFFAOYSA-N
- XLogP
- 5.7
- Polar surface area
- 85.5 Ų
- H-bond donors
- 3
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2019
- Admin. routes
- oral
- Indications
- neoplasm, central nervous system cancer, cutaneous melanoma, non-small cell lung carcinoma
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 560.271
- Has use
- medication
Show 4 more facts
- canonical SMILES
- CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6
- medical condition treated
- non-small-cell lung carcinoma
- chemical formula
- C₃₁H₃₄F₂N₆O₂
- subject has role
- protein kinase inhibitors
via Wikidata · CC0
~8 min read
Encyclopedic overview
11 sectionsContents
- Medical uses
- Side effects
- History
- Mechanism of action
- Clinical development
- Society and culture
- Legal status
- Economics
- Names
- References
- External links
Entrectinib, sold under the brand name Rozlytrek, is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (TRK) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK).
The most common side effects include tiredness, constipation, dysgeusia (taste disturbances), edema (swelling with fluid retention), dizziness, diarrhea, nausea (feeling sick), dysesthesia (unpleasant and abnormal feeling when touched), dyspnea (difficulty breathing), anemia (low red blood cell count), increased weight, increased blood creatinine (possible sign of kidney problems), pain, cognitive disorders (problems with ability to think, learn and remember), vomiting, cough, and fever.
Excerpted from Wikipedia’s “entrectinib” article, available under the CC BY-SA 4.0 licence.